מאמרים עם הרשאות לגישה ציבורית - Brian Riniלמידע נוסף
לא זמינים באתר כלשהו: 11
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...
The Lancet 393 (10189), 2404-2415, 2019
הרשאות: US National Institutes of Health
The immunology of renal cell carcinoma
CM Díaz-Montero, BI Rini, JH Finke
Nature Reviews Nephrology 16 (12), 721-735, 2020
הרשאות: US National Institutes of Health
Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma
BI Rini, Y Tomita, B Melichar, T Ueda, V Grünwald, MN Fishman, ...
Clinical genitourinary cancer 14 (6), 499-503, 2016
הרשאות: US National Institutes of Health
Blood myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in metastatic urothelial carcinoma
IY Sheng, CM Diaz-Montero, P Rayman, W Wei, JH Finke, JS Kim, ...
Targeted oncology 15, 211-220, 2020
הרשאות: US National Institutes of Health
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining
A Schwandt, JA Garcia, P Elson, J Wyckhouse, JH Finke, J Ireland, ...
Journal of clinical immunology 31, 690-698, 2011
הרשאות: US National Institutes of Health
Approaches to first-line therapy for metastatic clear cell renal cell carcinoma
YW Chen, BI Rini
Current Oncology Reports 24 (6), 695-702, 2022
הרשאות: US National Institutes of Health
Myeloid-derived suppressor cells in nonmetastatic urothelial carcinoma of bladder is associated with pathologic complete response and overall survival
J Fallah, CM Diaz-Montero, P Rayman, W Wei, JH Finke, JS Kim, ...
Clinical Genitourinary Cancer 18 (6), 500-508, 2020
הרשאות: US National Institutes of Health
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma
PK Tamukong, P Kuhlmann, S You, S Su, Y Wang, S Yoon, J Gong, ...
Urologic Oncology: Seminars and Original Investigations 40 (11), 495. e1-495 …, 2022
הרשאות: US National Institutes of Health
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma
M Apellániz-Ruiz, MH Diekstra, JM Roldán, E Boven, D Castellano, ...
Pharmacogenetics and Genomics 27 (6), 227-231, 2017
הרשאות: Government of Spain
Pharmacokinetically guided dosing of oral drugs: true precision oncology?
MC Ornstein, BI Rini
Clinical Cancer Research 22 (23), 5626-5628, 2016
הרשאות: US National Institutes of Health
Summary from the Kidney Cancer Association’s inaugural think thank: coalition for a cure
B Rini, EJ Abel, L Albiges, A Bex, J Brugarolas, RM Bukowski, ...
Clinical Genitourinary Cancer 19 (2), 167-175, 2021
הרשאות: Cancer Research UK, National Institute for Health Research, UK
זמינים באתר כלשהו: 171
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ...
New England Journal of Medicine 378 (14), 1277-1290, 2018
הרשאות: US National Institutes of Health
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
הרשאות: US National Institutes of Health
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
הרשאות: US National Institutes of Health, Fonds de recherche du Québec - Santé
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
הרשאות: US National Institutes of Health
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial
RJ Motzer, BI Rini, DF McDermott, BG Redman, TM Kuzel, MR Harrison, ...
Journal of clinical oncology 33 (13), 1430-1437, 2015
הרשאות: US National Institutes of Health
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ...
Journal of Clinical Oncology 26 (33), 5422-5428, 2008
הרשאות: US National Institutes of Health
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...
Nature medicine 24 (6), 749-757, 2018
הרשאות: US National Institutes of Health
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
הרשאות: US National Institutes of Health
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ...
Journal of clinical oncology 28 (13), 2137-2143, 2010
הרשאות: US National Institutes of Health
המידע על הפרסום ועל הגורמים המממנים נקבע באופן אוטומטי על ידי תוכנת מחשב